Anticoagulant News and Research

RSS

Statin use reduces stroke risks in patients with atrial fibrillation

...

16 Apr 2023

A randomized trial of a blood thinner after severe COVID-19 to prevent clotting events

In a recent prospective study published in the Annals of Internal Medicine Journal, researchers in the United States (US) and Spain performed a randomized controlled trial (RCT) across 127 US hospitals between 2021 and 2022.

27 Mar 2023

Venous thromboembolism is rare among non-hospitalized COVID-19 patients

In a recent study published in the journal JAMA Network Open, researchers in the United States assessed the risk and aimed to identify the independent predictors of venous thromboembolism events in outpatients who had less severe manifestations of coronavirus disease 2019 (COVID-19).

16 Mar 2023

Non-critically ill hospitalized Covid-19 patients could substantially benefit from a higher dose of blood-thinners

Giving noncritically ill patients hospitalized for COVID-19 a higher dose of blood-thinning medication than usual did not significantly reduce the combined risk of death from any cause, need for treatment in an intensive-care unit, a confirmed blood clot or a stroke at 30 days, according to the results of the FREEDOM-COVID trial presented at the American College of Cardiology's Annual Scientific Session Together With the World Congress of Cardiology.

6 Mar 2023

Researchers report two unusual COVID-19-related arrhythmic cases in children

Researchers explored the association between cardiac arrhythmias in children and COVID-19 infection.

8 Feb 2023

Early intervention key to managing diabetes, cardiorenal, and metabolic diseases

A panel of US-based experts in cardiology, nephrology, endocrinology, and primary care has prepared specific recommendations for early identification and intervention in obesity, diabetes, and other cardiorenal and metabolic diseases. A detailed report on recommended strategies has been published in the Journal of Diabetes and its Complications.

4 Jan 2023

Research offers a cost-effectiveness analysis of anticoagulant drugs for cancer-associated thrombosis

Newly published research out of the University of Cincinnati and the University of California-Davis shows that direct oral anticoagulant (DOAC) drugs are more effective and are more cost-effective than low molecular weight heparin for treating cancer-associated thrombosis.

4 Jan 2023

Cost-effectiveness analysis of four interventions for treatment of cancer-associated thrombosis

A cost-effectiveness analysis comparing direct oral anticoagulants (DOACs) to low-molecular-weight heparin (LMWH) found that DOACs are both more medically effective and cost-effective than LMWH when treating cancer-associated thrombosis (CAT).

27 Dec 2022

Direct oral anticoagulants more effective and cost-effective for treating cancer-associated thrombosis

Research conducted by UC Davis Comprehensive Cancer Center and the University of Cincinnati shows that direct oral anti-coagulant (DOAC) drugs are more effective and are more cost-effective than low molecular weight heparin (LMWH) for treating cancer-associated thrombosis (CAT).

27 Dec 2022

Review on nanoparticles usage for treating thrombosis induced by SARS-CoV-2 infections

Researchers provided an overview of nanomedicine strategies to treat coronavirus disease 2019 (COVID-19)-induced thrombosis.

21 Dec 2022

No benefit of low dose apixaban following acute COVID-19

The HEAL-COVID trial compared the efficacy of Apixaban to standard care in adults who have recently recovered from severe COVID-19.

14 Dec 2022

Natural material derived from seaweed can help improve outcomes after heart bypass surgery

Researchers are using a natural material derived from seaweed to promote vascular cell growth, prevent blood clots and improve the performance of synthetic vascular grafts used in heart bypass surgery.

5 Dec 2022

Oral anticoagulant does not help patients recovering from moderate and severe COVID-19

A drug used to reduce the risk of blood clots does not help patients recovering from moderate and severe COVID-19, despite this approach being offered to patients, a UK-wide trial, led by Addenbrooke's Hospital and the University of Cambridge has found.

28 Nov 2022

Additional six weeks of anti-clotting treatment reduces further clot risk after distal DVT

Giving the anti-clotting drug rivaroxaban to patients for 12 weeks instead of the usual six after a blood clot in the lower leg reduces the risk of further clots developing up to two years after treatment, finds a trial published by The BMJ today.

24 Nov 2022

Combination of three existing drugs extends survival in mouse models of lethal brain cancer

A Ludwig Cancer Research study has identified a combination of three existing drugs that significantly extends survival in mouse models of the lethal brain cancer glioblastoma multiforme (GBM).

20 Sep 2022

Reducing aspirin use in patients treated with common blood thinner prevents bleeding complications

If you're already taking one blood thinner, mounting research suggests you might not need to take a second one.

19 Sep 2022

Oral anticoagulant drug may be safe, effective in preventing blood clots after urologic cancer surgery

The oral anticoagulant drug apixaban may offer a safer, more effective alternative to standard home heparin injections for patients taking extended prophylaxis (EP) to prevent blood-clot-related complications after surgery, reports a study in The Journal of Urology, an Official Journal of the American Urological Association.

12 Sep 2022